Multisite study of the relationships between antemortem [ 11 C]PIB‐PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology

Neuropathological stageing of Alzheimer-related changes.

Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 1× · see citing works

The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): Part II. Standardization of the neuropathologic assessment of Alzheimer's disease

Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961 · see citing works

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B

Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496 · see citing works

Phases of Aβ-deposition in the human brain and its relevance for the development of AD

Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2002) · Neurology · doi:10.1212/wnl.58.12.1791 · Cited by 3,490 · see citing works

National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease

Hyman, B. T., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.10.007 · Cited by 3,092 · see citing works

The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET

Klunk, W. E., Koeppe, R. A., Price, J. C., Benzinger, T. L., Devous, M. D., Jagust, W. J., Johnson, K. A., Mathis, C. A., Minhas, D., Pontecorvo, M. J., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.07.003 · Cited by 1,348 · see citing works

Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease

Ikonomovic, M. D., Klunk, W. E., Abrahamson, E. E., Mathis, C. A., Price, J. C., Tsopelas, N. D., Lopresti, B. J., Ziolko, S., Bi, W., Paljug, W. R., et al. (2008) · Brain · doi:10.1093/brain/awn016 · Cited by 933 · see citing works

Defining imaging biomarker cut points for brain aging and Alzheimer's disease

Jack, C. R., Wiste, H. J., Weigand, S. D., Therneau, T. M., Lowe, V. J., Knopman, D. S., Gunter, J. L., Senjem, M. L., Jones, D. T., Kantarci, K., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.08.005 · Cited by 931 · see citing works

Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity

Palmqvist, S., Schöll, M., Strandberg, O., Mattsson, N., Stomrud, E., Zetterberg, H., Blennow, K., Landau, S., Jagust, W., & Hansson, O. (2017) · Nature Communications · doi:10.1038/s41467-017-01150-x · Cited by 911 · see citing works

Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study

Clark, C. M., Pontecorvo, M. J., Beach, T. G., Bedell, B. J., Coleman, R. E., Doraiswamy, P. M., Fleisher, A. S., Reiman, E. M., Sabbagh, M. N., Sadowsky, C. H., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70142-4 · Cited by 855 · see citing works

Appropriate use criteria for amyloid PET: a report of the amyloid imaging task force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association

Johnson, K. A., Minoshima, S., Bohnen, N. I., Donohoe, K. J., Foster, N. L., Herscovitch, P., Karlawish, J. H., Rowe, C. C., Carrillo, M. C., Hartley, D. M., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.01.002 · Cited by 603 · see citing works

In vivo staging of regional amyloid deposition

Grothe, M. J., Barthel, H., Sepulcre, J., Dyrba, M., Sabri, O., Teipel, S. J., Initiative, F. T. A. D. N., Initiative, A. D. N., Weiner, M., Aisen, P., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004643 · Cited by 440 · see citing works

Diagnostic Criteria for Neuropathologic Assessment of Alzheimer’s Disease

Braak, H., & Braak, E. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00062-6 · Cited by 410 · see citing works

Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation

Villeneuve, S., Rabinovici, G. D., Cohn-Sheehy, B. I., Madison, C., Ayakta, N., Ghosh, P. M., La Joie, R., Arthur-Bentil, S. K., Vogel, J. W., Marks, S. M., et al. (2015) · Brain · doi:10.1093/brain/awv112 · Cited by 408 · see citing works

Brain β-amyloid load approaches a plateau

Jack, C. R., Wiste, H. J., Lesnick, T. G., Weigand, S. D., Knopman, D. S., Vemuri, P., Pankratz, V. S., Senjem, M. L., Gunter, J. L., Mielke, M. M., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e3182840bbe · Cited by 406 · see citing works

Clinical and neuroanatomical signatures of tissue pathology in frontotemporal lobar degeneration

Rohrer, J. D., Lashley, T., Schott, J. M., Warren, J. D., Mead, S., Isaacs, A. M., Beck, J. A., Hardy, J., de Silva, R., Warrington, E. K., et al. (2011) · Brain · doi:10.1093/brain/awr198 · Cited by 359 · see citing works

Phase 3 Trial of Flutemetamol Labeled With Radioactive Fluorine 18 Imaging and Neuritic Plaque Density

Curtis, C., Gamez, J. E., Singh, U., Sadowsky, C. H., Villena, T., Sabbagh, M. N., Beach, T. G., Duara, R., Fleisher, A. S., Frey, K. A., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.4144 · Cited by 332 · see citing works

Appropriate Use Criteria for Amyloid PET: A Report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association

Johnson, K. A., Minoshima, S., Bohnen, N. I., Donohoe, K. J., Foster, N. L., Herscovitch, P., Karlawish, J. H., Rowe, C. C., Carrillo, M. C., Hartley, D. M., et al. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.120618 · Cited by 329 · see citing works

Clinicopathologic and¹¹C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer’s disease spectrum

Murray, M. E., Lowe, V. J., Graff-Radford, N. R., Liesinger, A. M., Cannon, A., Przybelski, S. A., Rawal, B., Parisi, J. E., Petersen, R. C., Kantarci, K., et al. (2015) · Brain · doi:10.1093/brain/awv050 · Cited by 324 · see citing works

Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD

Rabinovici, G. D., Rosen, H. J., Alkalay, A., Kornak, J., Furst, A. J., Agarwal, N., Mormino, E. C., O'Neil, J. P., Janabi, M., Karydas, A., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31823b9c5e · Cited by 318 · see citing works

The importance of appropriate partial volume correction for PET quantification in Alzheimer’s disease

Thomas, B. A., Erlandsson, K., Marc Modat, A., Thurfjell, L., Vandenberghe, R. R., Sebastien Ourselin, A., & Hutton, B. F. (2011) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-1745-9 · Cited by 317 · see citing works

Clinicopathological correlations in behavioural variant frontotemporal dementia

Perry, D. C., Brown, J. A., Possin, K. L., Datta, S., Trujillo, A., Radke, A., Karydas, A., Kornak, J., Sias, A. C., Rabinovici, G. D., et al. (2017) · Brain · doi:10.1093/brain/awx254 · Cited by 309 · see citing works

Amyloid PET imaging in Alzheimer’s disease: a comparison of three radiotracers

Initiative, T. A. D. N., Landau, S. M., Thomas, B. A., Thurfjell, L., Schmidt, M. E., Margolin, R. A., Mintun, M. A., Pontecorvo, M. J., Baker, S. L., & Jagust, W. J. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2753-3 · Cited by 294 · see citing works

In vivo staging of regional amyloid deposition

Grothe, M. J., Barthel, H., Sepulcre, J., Dyrba, M., Sabri, O., Teipel, S. J., Stern, Y., & Initiative, A. D. N. (2022) · DZNE Pub · doi:10.7916/0vj1-4c02 · Cited by 294 · see citing works

Increased metabolic vulnerability in early-onset Alzheimer’s disease is not related to amyloid burden

Rabinovici, G. D., Furst, A. J., Alkalay, A., Racine, C. A., O’Neil, J. P., Janabi, M., Baker, S. L., Agarwal, N., Bonasera, S. J., Mormino, E. C., et al. (2010) · Brain · doi:10.1093/brain/awp326 · Cited by 280 · see citing works

Associations Between Serum Cholesterol Levels and Cerebral Amyloidosis

Reed, B., Villeneuve, S., Mack, W., DeCarli, C., Chui, H. C., & Jagust, W. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2013.5390 · Cited by 267 · see citing works

Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer’s disease: a voxelwise PiB–PET longitudinal study

Villain, N., Chételat, G., Grassiot, B., Bourgeat, P., Jones, G., Ellis, K. A., Ames, D., Martins, R. N., Eustache, F., Salvado, O., et al. (2012) · Brain · doi:10.1093/brain/aws125 · Cited by 255 · see citing works

Partial volume correction in quantitative amyloid imaging

Su, Y., Blazey, T. M., Snyder, A. Z., Raichle, M. E., Marcus, D. S., Ances, B. M., Bateman, R. J., Cairns, N. J., Aldea, P., Cash, L., et al. (2015) · NeuroImage · doi:10.1016/j.neuroimage.2014.11.058 · Cited by 247 · see citing works

Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study

Fleisher, A., Chen, K., Quiroz, Y. T., Jakimovich, L. J., Gomez, M. G., Langois, C. M., Langbaum, J. B. S., Ayutyanont, N., Roontiva, A., Thiyyagura, P., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70227-2 · Cited by 242 · see citing works

Amyloid Angiopathy and Variability in Amyloid β Deposition Is Determined by Mutation Position in Presenilin-1-Linked Alzheimer’s Disease

Mann, D. M. A., Pickering-Brown, S. M., Takeuchi, A., & Iwatsubo, T. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64688-3 · Cited by 182 · see citing works

18F-Florbetaben PET beta-amyloid binding expressed in Centiloids

Rowe, C. C., Doré, V., Jones, G. R., Baxendale, D., Mulligan, R. S., Bullich, S., Stephens, A. W., Santi, S. D., Masters, C. L., Dinkelborg, L. M., et al. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3749-6 · Cited by 178 · see citing works

High Striatal Amyloid β-Peptide Deposition Across Different Autosomal Alzheimer Disease Mutation Types

Villemagne, V. L., Ataka, S., Mizuno, T., Brooks, W. S., Wada, Y., Kondo, M., Jones, G. R., Watanabe, Y., Mulligan, R. S., Nakagawa, M., et al. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.285 · Cited by 171 · see citing works

Standardized Expression of 18F-NAV4694 and 11C-PiB β-Amyloid PET Results with the Centiloid Scale

Rowe, C. C., Jones, G. R., Doré, V., Pejoska, S., Margison, L., Mulligan, R. S., Chan, J. G., Young, K., & Villemagne, V. L. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.171595 · Cited by 141 · see citing works

Magnetic Resonance Imaging Signatures of Tissue Pathology in Frontotemporal Dementia

Whitwell, J. L., Josephs, K. A., Rossor, M. N., Stevens, J., Révész, T., Holton, J. L., Al‐Sarraj, S., Godbolt, A. K., Fox, N. C., & Warren, J. D. (2005) · Archives of Neurology · doi:10.1001/archneur.62.9.1402 · Cited by 137 · see citing works

Pittsburgh compound B imaging and cerebrospinal fluid amyloid-β in a multicentre European memory clinic study

Leuzy, A., Chiotis, K., Hasselbalch, S. G., Rinne, J. O., de Mendonça, A., Otto, M., Lleó, A., Castelo-Branco, M. S., Santana, I. J., Johansson, J. J., et al. (2016) · Brain · doi:10.1093/brain/aww160 · Cited by 132 · see citing works

In Vivo Fibrillar β-Amyloid Detected Using [11C]PiB Positron Emission Tomography and Neuropathologic Assessment in Older Adults

Sojkova, J., Driscoll, I. F., Iacono, D., Zhou, Y., Codispoti, K.-E., Kraut, M. A., Ferrucci, L., Pletniková, O., Mathis, C. A., Klunk, W. E., et al. (2011) · Archives of Neurology · doi:10.1001/archneurol.2010.357 · Cited by 112 · see citing works

Using Pittsburgh Compound B for In Vivo PET Imaging of Fibrillar Amyloid-Beta

Cohen, A. D., Rabinovici, G. D., Mathis, C. A., Jagust, W. J., Klunk, W. E., & Ikonomović, M. D. (2012) · Advances in pharmacology · doi:10.1016/b978-0-12-394816-8.00002-7 · Cited by 99 · see citing works

Classification of amyloid-positivity in controls: Comparison of visual read and quantitative approaches

Cohen, A. D., Mowrey, W. B., Weissfeld, L. A., Aizenstein, H. J., McDade, E., Mountz, J. M., Nebes, R. D., Saxton, J. A., Snitz, B. E., DeKosky, S. T., et al. (2013) · NeuroImage · doi:10.1016/j.neuroimage.2013.01.015 · Cited by 97 · see citing works

Early AD pathology in a [C-11]PiB-negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study

Ikonomovic, M., Abrahamson, E., Price, J., Hamilton, R., Mathis, C., Paljug, W. R., Debnath, M., Cohen, A., Mizukami, K., Dekosky, S., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-0943-2 · Cited by 90 · see citing works

Performance of [¹⁸F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA‐AA recommendations for the neuropathologic diagnosis of Alzheimer's disease

Salloway, S., Gamez, J. E., Singh, U., Sadowsky, C. H., Villena, T., Sabbagh, M. N., Beach, T. G., Duara, R., Fleisher, A. S., Frey, K. A., et al. (2017) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.06.001 · Cited by 87 · see citing works

Ante mortem amyloid imaging and β-amyloid pathology in a case with dementia with Lewy bodies

Kantarci, K., Yang, C., Schneider, J. A., Senjem, M. L., Reyes, D. A., Lowe, V. J., Barnes, L. L., Aggarwal, N. T., Bennett, D. A., Smith, G. E., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.08.007 · Cited by 70 · see citing works

Presenile Alzheimer disease

Pro, J. D. Z., Smith, M. C. H., & Sumi, S. M. (1980) · Neurology · doi:10.1212/wnl.30.8.820 · Cited by 64 · see citing works

Regional correlations between [11C]PIB PET and post-mortem burden of amyloid-beta pathology in a diverse neuropathological cohort

Seo, S. W., Ayakta, N., Grinberg, L. T., Villeneuve, S., Lehmann, M., Reed, B., DeCarli, C., Miller, B. L., Rosen, H. J., Boxer, A. L., et al. (2017) · NeuroImage: Clinical · doi:10.1016/j.nicl.2016.11.008 · Cited by 63 · see citing works

Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer’s Disease: Results from the DIAN Study Group

Su, Y., Blazey, T. M., Owen, C. J., Christensen, J. J., Friedrichsen, K., Joseph-Mathurin, N., Wang, Q., Hornbeck, R. C., Ances, B. M., Snyder, A. Z., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0152082 · Cited by 56 · see citing works

Can target-to-pons ratio be used as a reliable method for the analysis of [11C]PIB brain scans?

Edison, P., Hinz, R., Ramlackhansingh, A. F., Thomas, J., Gelosa, G., Archer, H. A., Turkheimer, F., & Brooks, D. J. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2012.01.099 · Cited by 39 · see citing works

Hallazgos neuropatológicos en la enfermedad de Alzheimer de inicio temprano (mutación E280A-PS1)

Duque-Castaño, A., Mi, R., Arango-Viana, J. C., Arcos-Burgos, M., Cubillo, H., & Lopera, F. (1999) · Revista de Neurología · doi:10.33588/rn.2901.99122 · Cited by 12 · see citing works

Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup

Jack, C. R., Andrews, J. S., Beach, T. G., Buracchio, T., Dunn, B., Graf, A., Hansson, O., Ho, C., Jagust, W., McDade, E., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13859 · Cited by 2,803 · see citing works

Clinical diagnosis of Alzheimer’s disease: Recommendations of the International Working Group

Dubois, B., Villain, N., Frisoni, G. B., Rabinovici, G. D., Sabbagh, M., Cappa, S., Bejanin, A., Bombois, S., Epelbaum, S., Teichmann, M., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00066-1 · Cited by 1,051 · see citing works

Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration

Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) investigators, Thijssen, E. H., La Joie, R., Wolf, A., Strom, A., Wang, P., Iaccarino, L., Bourakova, V., Cobigo, Y., Heuer, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0762-2 · Cited by 761 · see citing works

The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics

Karran, E., & De Strooper, B. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00391-w · Cited by 742 · see citing works

Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study

Thijssen, E. H., La Joie, R., Strom, A., Fonseca, C., Iaccarino, L., Wolf, A., Spina, S., Allen, I. E., Cobigo, Y., Heuer, H., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00214-3 · Cited by 607 · see citing works

Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring

Ashton, N. J., Janelidze, S., Mattsson-Carlgren, N., Binette, A. P., Strandberg, O., Brum, W. S., Karikari, T. K., González-Ortiz, F., Di Molfetta, G., Meda, F. J., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02074-w · Cited by 436 · see citing works

Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ pathology are detected

Suárez‐Calvet, M., Karikari, T. K., Ashton, N. J., Lantero Rodríguez, J., Milà‐Alomà, M., Gispert, J. D., Salvadó, G., Minguillon, C., Fauria, K., Shekari, M., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.202012921 · Cited by 401 · see citing works

Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease

Milà-Alomà, M., Ashton, N. J., Shekari, M., Salvadó, G., Ortiz-Romero, P., Montoliu-Gaya, L., Benedet, A. L., Karikari, T. K., Lantero-Rodriguez, J., Vanmechelen, E., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01925-w · Cited by 353 · see citing works

APOE4 homozygosity represents a distinct genetic form of Alzheimer’s disease

Fortea, J., Pegueroles, J., Alcolea, D., Belbin, O., Dols-Icardo, O., Vaqué-Alcázar, L., Videla, L., Gispert, J. D., Suárez-Calvet, M., Johnson, S. C., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02931-w · Cited by 369 · see citing works

Hypothesis: Tau pathology is an initiating factor in sporadic Alzheimer's disease

Arnsten, A. F. T., Datta, D., Del Tredici, K., & Braak, H. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12192 · Cited by 361 · see citing works

Alzheimer's disease: From immunotherapy to immunoprevention

Jucker, M., & Walker, L. C. (2023) · Cell · doi:10.1016/j.cell.2023.08.021 · Cited by 353 · see citing works

The AHEAD 3‐45 Study: Design of a prevention trial for Alzheimer's disease

Rafii, M. S., Sperling, R. A., Donohue, M. C., Zhou, J., Roberts, C., Irizarry, M. C., Dhadda, S., Sethuraman, G., Kramer, L. D., Swanson, C. J., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12748 · Cited by 291 · see citing works

Comorbid neuropathological diagnoses in early versus late-onset Alzheimer's disease

Spina, S., La Joie, R., Petersen, C., Nolan, A. L., Cuevas, D., Cosme, C., Hepker, M., Hwang, J.-H., Miller, Z. A., Huang, E. J., et al. (2021) · Brain · doi:10.1093/brain/awab099 · Cited by 278 · see citing works

The Role of Amyloid PET in Imaging Neurodegenerative Disorders: A Review

Chapleau, M., Iaccarino, L., Soleimani‐Meigooni, D. N., & Rabinovici, G. D. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263195 · Cited by 264 · see citing works

Donanemab: Appropriate use recommendations

Rabinovici, G. D., Selkoe, D. J., Schindler, S. E., Aisen, P., Apostolova, L. G., Atri, A., Greenberg, S. M., Hendrix, S. B., Petersen, R. C., Weiner, M., et al. (2025) · The Journal of Prevention of Alzheimer's Disease · doi:10.1016/j.tjpad.2025.100150 · Cited by 278 · see citing works

Validation of amyloid PET positivity thresholds in centiloids: a multisite PET study approach

Initiative, F. T. A. D. N., Royse, S. K., Minhas, D. S., Lopresti, B. J., Murphy, A., Ward, T., Koeppe, R. A., Bullich, S., DeSanti, S., Jagust, W. J., et al. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00836-1 · Cited by 237 · see citing works

Time course of phosphorylated-tau181 in blood across the Alzheimer’s disease spectrum

Moscoso, A., Grothe, M. J., Ashton, N. J., Karikari, T. K., Rodriguez, J. L., Snellman, A., Suárez-Calvet, M., Zetterberg, H., Blennow, K., Schöll, M., et al. (2021) · Brain · doi:10.1093/brain/awaa399 · Cited by 229 · see citing works

Quantification of amyloid PET for future clinical use: a state-of-the-art review

Pemberton, H. G., Collij, L. E., Heeman, F., Bollack, A., Shekari, M., Salvadó, G., Alves, I. L., Garcia, D. V., Battle, M., Buckley, C., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05784-y · Cited by 226 · see citing works

Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial

Shcherbinin, S., Evans, C. D., Lu, M., Andersen, S. W., Pontecorvo, M. J., Willis, B. A., Gueorguieva, I., Hauck, P. M., Brooks, D. A., Mintun, M. A., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.2793 · Cited by 210 · see citing works

Updates in Alzheimer's disease: from basic research to diagnosis and therapies

Liu, E., Zhang, Y., & Wang, J. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00432-x · Cited by 220 · see citing works

Biomarker-based staging of Alzheimer disease: rationale and clinical applications

Therriault, J., Schindler, S. E., Salvadó, G., Pascoal, T. A., Benedet, A. L., Ashton, N. J., Karikari, T. K., Apostolova, L. G., Murray, M. E., Verberk, I. M. W., et al. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-00942-2 · Cited by 206 · see citing works

The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes

Jack, C. R., Wiste, H. J., Botha, H., Weigand, S. D., Therneau, T. M., Knopman, D. S., Graff-Radford, J., Jones, D. T., Ferman, T. J., Boeve, B. F., et al. (2019) · Brain · doi:10.1093/brain/awz268 · Cited by 200 · see citing works

Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers

for the Alzheimer’s Disease Neuroimaging Initiative, F. T. A. S., Salvadó, G., Molinuevo, J. L., Brugulat-Serrat, A., Falcon, C., Grau-Rivera, O., Suárez-Calvet, M., Pavia, J., Niñerola-Baizán, A., Perissinotti, A., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0478-z · Cited by 195 · see citing works

Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer’s disease

Amadoru, S., Doré, V., McLean, C. A., Hinton, F., Shepherd, C. E., Halliday, G. M., Leyton, C. E., Yates, P. A., Hodges, J. R., Masters, C. L., et al. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00587-5 · Cited by 181 · see citing works

Plasma Aβ42/Aβ40 and phospho‐tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer's disease

Rissman, R. A., Langford, O., Raman, R., Donohue, M. C., Abdel‐Latif, S., Meyer, M. R., Wente‐Roth, T., Kirmess, K. M., Ngolab, J., Winston, C. N., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13542 · Cited by 157 · see citing works

Dissecting the clinical heterogeneity of early-onset Alzheimer’s disease

Sirkis, D. W., Bonham, L. W., Johnson, T. P., La Joie, R., & Yokoyama, J. S. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01531-9 · Cited by 151 · see citing works

Plasma Tau and Neurofilament Light in Frontotemporal Lobar Degeneration and Alzheimer Disease

Illán-Gala, I., Lleo, A., Karydas, A., Staffaroni, A. M., Zetterberg, H., Sivasankaran, R., Grinberg, L. T., Spina, S., Kramer, J. H., Ramos, E. M., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000011226 · Cited by 150 · see citing works

Predicting amyloid PET and tau PET stages with plasma biomarkers

Jack, C. R., Wiste, H. J., Algeciras‐Schimnich, A., Figdore, D. J., Schwarz, C. G., Lowe, V. J., Ramanan, V. K., Vemuri, P., Mielke, M. M., Knopman, D. S., et al. (2023) · Brain · doi:10.1093/brain/awad042 · Cited by 149 · see citing works

Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup

Rabinovici, G. D., Knopman, D. S., Arbizu, J., Benzinger, T. L. S., Donohoe, K. J., Hansson, O., Herscovitch, P., Kuo, P. H., Lingler, J. H., Minoshima, S., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14338 · Cited by 151 · see citing works

New landscape of the diagnosis of Alzheimer’s disease

Frisoni, G. B., Hansson, O., Nichols, E., Garibotto, V., Schindler, S. E., van der Flier, W. M., Jessen, F., Villain, N., Arenaza-Urquijo, E. M., Crivelli, L., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01294-2 · Cited by 143 · see citing works

Comparison of Pittsburgh compound B and florbetapir in cross‐sectional and longitudinal studies

Su, Y., Flores, S. E., Wang, G., Hornbeck, R. C., Speidel, B. A., Joseph‐Mathurin, N., Vlassenko, A. G., Gordon, B. A., Koeppe, R. A., Klunk, W. E., et al. (2019) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2018.12.008 · Cited by 140 · see citing works

Cerebrospinal Fluid Biomarkers in Autopsy-Confirmed Alzheimer Disease and Frontotemporal Lobar Degeneration

Mattsson, N., Grinberg, L. T., Boxer, A. L., Ossenkoppele, R., Jonsson, M., Seeley, W., Ehrenberg, A. J., Spina, S., Janelidze, S., Rojas-Martinex, J., et al. (2022) · Neurology · doi:10.1212/wnl.0000000000200040 · Cited by 136 · see citing works

Plasma Phosphorylated Tau 217 and Aβ42/40 to Predict Early Brain Aβ Accumulation in People Without Cognitive Impairment

Janelidze, S., Barthélemy, N. R., Salvadó, G., Schindler, S. E., Palmqvist, S., Mattsson, N., Braunstein, J. B., Ovod, V., Bollinger, J. G., He, Y., et al. (2024) · JAMA Neurology · doi:10.1001/jamaneurol.2024.2619 · Cited by 135 · see citing works

Defining the Lowest Threshold for Amyloid-PET to Predict Future Cognitive Decline and Amyloid Accumulation

Farrell, M. E., Jiang, S., Schultz, A. P., Properzi, M. J., Price, J. C., Becker, J. A., Jacobs, H. I. L., Hanseeuw, B. J., Rentz, D. M., Villemagne, V. L., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000011214 · Cited by 129 · see citing works

Increasing participant diversity in AD research: plans for digital screening, blood testing, and a community-engaged approach in the Alzheimer’s Disease Neuroimaging Initiative 4

Weiner, M. W., Veitch, D. P., Miller, M. J., Aisen, P. S., Albala, B., Beckett, L. A., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12797 · Cited by 126 · see citing works

Association Between Ambient Air Pollution and Amyloid Positron Emission Tomography Positivity in Older Adults With Cognitive Impairment

Iaccarino, L., Joie, R. L., Lesman‐Segev, O. H., Lee, E. Y., Hanna, L., Allen, I. E., Hillner, B. E., Siegel, B. A., Whitmer, R. A., Carrillo, M. C., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.3962 · Cited by 117 · see citing works

Centiloid recommendations for clinical context‐of‐use from the AMYPAD consortium

Collij, L. E., Bollack, A., Joie, R. L., Shekari, M., Bullich, S., Roé-Vellvé, N., Koglin, N., Jovalekic, A., García, D. V., Drzezga, A. E., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14336 · Cited by 126 · see citing works

Clinical validation of the PrecivityAD2 blood test: A mass spectrometry‐based test with algorithm combining %p‐tau217 and Aβ42/40 ratio to identify presence of brain amyloid

Meyer, M. R., Kirmess, K. M., Eastwood, S., Wente‐Roth, T. L., Irvin, F., Holubasch, M. S., Venkatesh, V., Fogelman, I., Monane, M., Hanna, L., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13764 · Cited by 126 · see citing works

Assessment of a Plasma Amyloid Probability Score to Estimate Amyloid Positron Emission Tomography Findings Among Adults With Cognitive Impairment

Hu, Y., Kirmess, K. M., Meyer, M. R., Rabinovici, G. D., Gatsonis, C., Siegel, B. A., Whitmer, R. A., Apgar, C., Hanna, L., Kanekiyo, M., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.8392 · Cited by 120 · see citing works

Comparison of ¹⁸F‐florbetaben quantification results using the standard Centiloid, MR‐based, and MR‐less CapAIBL^® approaches: Validation against histopathology

Doré, V., Bullich, S., Rowe, C. C., Bourgeat, P., Konate, S., Sabri, O., Stephens, A. W., Barthel, H., Fripp, J., Masters, C. L., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.02.005 · Cited by 93 · see citing works

Blood phosphorylated tau for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis

Therriault, J., Brum, W. S., Trudel, L., Macedo, A. C., Bitencourt, F. V., Martins, C. C., Nakouzi, M., Pola, I., Wong, M. W. K., Kac, P. R., et al. (2025) · The Lancet Neurology · doi:10.1016/s1474-4422(25)00227-3 · Cited by 114 · see citing works

Pyroglutamate Aβ cascade as drug target in Alzheimer’s disease

Bayer, T. A. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01409-2 · Cited by 98 · see citing works

Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease

Leuzy, A., Bollack, A., Pellegrino, D., Teunissen, C. E., Joie, R. L., Rabinovici, G. D., Franzmeier, N., Johnson, K. A., Barkhof, F., Shaw, L. M. J., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14528 · Cited by 97 · see citing works

Optimizing cutpoints for clinical interpretation of brain amyloid status using plasma p‐tau217 immunoassays

Figdore, D. J., Griswold, M. E., Bornhorst, J. A., Graff‐Radford, J., Ramanan, V. K., Vemuri, P., Lowe, V. J., Knopman, D. S., Jack, C. R., Petersen, R. C., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14140 · Cited by 94 · see citing works

Relationship between amyloid and tau levels and its impact on tau spreading

Doré, V., Krishnadas, N., Bourgeat, P., Huang, K., Li, S., Burnham, S. C., Masters, C. L., Fripp, J., Villemagne, V. L., & Rowe, C. C. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05191-9 · Cited by 93 · see citing works

Associations of Fully Automated CSF and Novel Plasma Biomarkers With Alzheimer Disease Neuropathology at Autopsy

Grothe, M. J., Moscoso, A., Ashton, N. J., Karikari, T. K., Lantero‐Rodriguez, J., Snellman, A., Zetterberg, H., Blennow, K., Schöll, M., & Initiative, A. D. N. (2021) · Neurology · doi:10.1212/wnl.0000000000012513 · Cited by 96 · see citing works

Detection of Alzheimer's disease amyloid beta 1‐42, p‐tau, and t‐tau assays

van Harten, A. C., Wiste, H. J., Weigand, S. D., Mielke, M. M., Kremers, W. K., Eichenlaub, U., Dyer, R. B., Algeciras‐Schimnich, A., Knopman, D. S., Jack, C. R., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12406 · Cited by 91 · see citing works

Amyloid, tau and metabolic PET correlates of cognition in early and late-onset Alzheimer’s disease

Tanner, J. A., Iaccarino, L., Edwards, L., Asken, B. M., Gorno‐Tempini, M. L., Kramer, J. H., Pham, J. Q., Perry, D. C., Possin, K. L., Malpetti, M., et al. (2022) · Brain · doi:10.1093/brain/awac229 · Cited by 88 · see citing works

Acute targeting of pre-amyloid seeds in transgenic mice reduces Alzheimer-like pathology later in life

Uhlmann, R. E., Rother, C., Rasmussen, J., Schelle, J., Bergmann, C., Ullrich Gavilanes, E. M., Fritschi, S. K., Buehler, A., Baumann, F., Skodras, A., et al. (2020) · Nature Neuroscience · doi:10.1038/s41593-020-00737-w · Cited by 87 · see citing works

The central role of tau in Alzheimer’s disease: From neurofibrillary tangle maturation to the induction of cell death

Thal, D. R., & Tomé, S. O. (2022) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2022.10.006 · Cited by 85 · see citing works

Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer's Disease

Gueorguieva, I., Willis, B. A., Chua, L., Chow, K. H., Ernest, C. S., Shcherbinin, S., Ardayfio, P. A., Mullins, G. R., & Sims, J. R. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2875 · Cited by 86 · see citing works

Association of β-Amyloid Level, Clinical Progression, and Longitudinal Cognitive Change in Normal Older Individuals

van der Kall, L. M., Truong, T. H., Burnham, S. C., Doré, V., Mulligan, R. S., Bozinovski, S., Lamb, F., Bourgeat, P., Fripp, J., Schultz, S. A., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000011222 · Cited by 84 · see citing works

Defining a Centiloid scale threshold predicting long-term progression to dementia in patients attending the memory clinic: an [18F] flutemetamol amyloid PET study

Hanseeuw, B. J., Malotaux, V., Dricot, L., Quenon, L., Sznajer, Y., Cerman, J., Woodard, J. L., Buckley, C. J., Farrar, G., Ivanoiu, A., et al. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04942-4 · Cited by 83 · see citing works

A multicenter comparison of [18F]flortaucipir, [18F]RO948, and [18F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis

Leuzy, A., Pascoal, T. A., Strandberg, O. T., Insel, P. S., Smith, R. A., Mattsson, N., Benedet, A. L., Cho, H., Lyoo, C. H., Joie, R. L., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05401-4 · Cited by 86 · see citing works

Tau PET and multimodal brain imaging in patients at risk for chronic traumatic encephalopathy

Lesman‐Segev, O. H., Joie, R. L., Stephens, M. L., Sonni, I., Tsai, R. M., Bourakova, V., Visani, A. V., Edwards, L., O’Neil, J. P., Baker, S. L., et al. (2019) · NeuroImage Clinical · doi:10.1016/j.nicl.2019.102025 · Cited by 81 · see citing works

Relevance of biomarkers across different neurodegenerative diseases

Ehrenberg, A. J., Khatun, A., Coomans, E. M., Betts, M. J., Capraro, F., Thijssen, E. H., Senkevich, K. A., Bharucha, T., Jafarpour, M., Young, P. N. E., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00601-w · Cited by 79 · see citing works

Diagnostic Accuracy of Amyloid versus18F‐Fluorodeoxyglucose Positron Emission Tomography in Autopsy‐Confirmed Dementia

Lesman‐Segev, O. H., Joie, R. L., Iaccarino, L., Lobach, I. V., Rosen, H. J., Seo, S. W., Janabi, M., Baker, S. L., Edwards, L., Pham, J. Q., et al. (2020) · Annals of Neurology · doi:10.1002/ana.25968 · Cited by 79 · see citing works

Amyloid and tau‐PET in early‐onset AD: Baseline data from the Longitudinal Early‐onset Alzheimer's Disease Study (LEADS)

Cho, H., Mundada, N. S., Apostolova, L. G., Carrillo, M. C., Shankar, R. P., Amuiri, A. N., Zeltzer, E., Windon, C., Soleimani‐Meigooni, D. N., Tanner, J. A., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13453 · Cited by 78 · see citing works

Updated Appropriate Use Criteria for Amyloid and Tau PET: A Report from the Alzheimer’s Association and Society for Nuclear Medicine and Molecular Imaging Workgroup

Rabinovici, G. D., Knopman, D. S., Arbizu, J., Benzinger, T. L. S., Donohoe, K. J., Hansson, O., Herscovitch, P., Kuo, P. H., Lingler, J. H., Minoshima, S., et al. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.268756 · Cited by 82 · see citing works

Amyloid‐β PET in Alzheimer's disease: A systematic review and Bayesian meta‐analysis

Ruan, D., & Sun, L. (2022) · Brain and Behavior · doi:10.1002/brb3.2850 · Cited by 77 · see citing works

Neuroimaging in Frontotemporal Dementia: Heterogeneity and Relationships with Underlying Neuropathology

Peet, B. T., Spina, S., Mundada, N., & La Joie, R. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01101-x · Cited by 74 · see citing works

Early detection of amyloid load using 18F-florbetaben PET

Bullich, S., Roé-Vellvé, N., Marquié, M., Landau, S. M., Barthel, H., Villemagne, V. L., Sanabria, Á., Tartari, J. P., Sotolongo-Grau, O., Doré, V., et al. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00807-6 · Cited by 71 · see citing works

Plasma Phosphorylated Tau 217 to Identify Preclinical Alzheimer Disease

Salvadó, G., Janelidze, S., Bali, D., Dolado, A. O., Therriault, J., Brum, W. S., Binette, A. P., Stomrud, E., Mattsson, N., Palmqvist, S., et al. (2025) · JAMA Neurology · doi:10.1001/jamaneurol.2025.3217 · Cited by 71 · see citing works

Visual assessment of [18F]flutemetamol PET images can detect early amyloid pathology and grade its extent

Collij, L. E., Salvadó, G., Shekari, M., Alves, I. L., Reimand, J., Wink, A. M., Zwan, M. D., Niñerola‐Baizán, A., Perissinotti, A., Scheltens, P., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-05174-2 · Cited by 69 · see citing works

ApoE4 and Connectivity-Mediated Spreading of Tau Pathology at Lower Amyloid Levels

Steward, A., Biel, D., Dewenter, A., Roemer, S., Wagner, F., Dehsarvi, A., Rathore, S., Otero Svaldi, D., Higgins, I., Brendel, M., et al. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2023.4038 · Cited by 67 · see citing works

Frequency and Clinical Outcomes Associated With Tau Positron Emission Tomography Positivity

Moscoso, A., Heeman, F., Raghavan, S., Costoya‐Sánchez, A., van Essen, M., Mainta, I., Camacho, V., Fonseca, O. D. R., Silva‐Rodríguez, J., Perissinotti, A., et al. (2025) · JAMA · doi:10.1001/jama.2025.7817 · Cited by 70 · see citing works

PET molecular imaging for pathophysiological visualization in Alzheimer’s disease

Wang, J., Jin, C., Zhou, J., Zhou, R., Tian, M., Lee, H. J., & Zhang, H. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05999-z · Cited by 66 · see citing works

rPOP: Robust PET-only processing of community acquired heterogeneous amyloid-PET data

Iaccarino, L., Joie, R. L., Koeppe, R. A., Siegel, B. A., Hillner, B. E., Gatsonis, C. A., Whitmer, R. A., Carrillo, M. C., Apgar, C., Camacho, M. R., et al. (2021) · NeuroImage · doi:10.1016/j.neuroimage.2021.118775 · Cited by 64 · see citing works

The Spatial-Temporal Ordering of Amyloid Pathology and Opportunities for PET Imaging

Fantoni, E., Collij, L. E., Alves, I. L., Buckley, C. J., & Farrar, G. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.235879 · Cited by 63 · see citing works

Association of Initial β-Amyloid Levels With Subsequent Flortaucipir Positron Emission Tomography Changes in Persons Without Cognitive Impairment

Knopman, D. S., Lundt, E. S., Therneau, T. M., Albertson, S. M., Gunter, J. L., Senjem, M. L., Schwarz, C. G., Mielke, M. M., Machulda, M. M., Boeve, B. F., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2020.3921 · Cited by 61 · see citing works

Retina pathology as a target for biomarkers for Alzheimer's disease: Current status, ophthalmopathological background, challenges, and future directions

Alber, J., Bouwman, F. H., den Haan, J., Rissman, R. A., Groef, L. D., Koronyo‐Hamaoui, M., Lengyel, I., & Thal, D. R. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13529 · Cited by 61 · see citing works

A practical overview of the use of amyloid-PET Centiloid values in clinical trials and research

Iaccarino, L., Burnham, S. C., Tunali, I., Wang, J., Navitsky, M. A., Arora, A., & Pontecorvo, M. J. (2025) · NeuroImage Clinical · doi:10.1016/j.nicl.2025.103765 · Cited by 63 · see citing works

Plasma p217+tau versus NAV4694 amyloid and MK6240 tau PET across the Alzheimer's continuum

Doré, V., Doecke, J. D., Saad, Z. S., Triana‐Baltzer, G., Slemmon, R., Krishnadas, N., Bourgeat, P., Huang, K., Burnham, S. C., Fowler, C. J., et al. (2022) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12307 · Cited by 60 · see citing works

Sensitivity–Specificity of Tau and Amyloid β Positron Emission Tomography in Frontotemporal Lobar Degeneration

Ghirelli, A., Tosakulwong, N., Weigand, S. D., Clark, H. M., Ali, F., Botha, H., Duffy, J. R., Utianski, R. L., Buciuc, M., Murray, M. E., et al. (2020) · Annals of Neurology · doi:10.1002/ana.25893 · Cited by 59 · see citing works

Plasma pTau217 predicts continuous brain amyloid levels in preclinical and early Alzheimer's disease

Devanarayan, V., Doherty, T., Charil, A., Sachdev, P., Ye, Y., Murali, L. K., Llano, D. A., Zhou, J., Reyderman, L., Hampel, H. J., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14073 · Cited by 59 · see citing works

Regional Tau Effects on Prospective Cognitive Change in Cognitively Normal Older Adults

Chen, X., Cassady, K. E., Adams, J. N., Harrison, T. M., Baker, S. L., & Jagust, W. J. (2020) · Journal of Neuroscience · doi:10.1523/jneurosci.2111-20.2020 · Cited by 58 · see citing works

Accuracy of Biomarker Testing for Neuropathologically Defined Alzheimer Disease in Older Adults With Dementia: A Systematic Review

Fink, H. A., Linskens, E. J., Silverman, P. C., McCarten, J. R., Hemmy, L. S., Ouellette, J. M., Greer, N. L., Wilt, T. J., & Butler, M. (2020) · Annals of Internal Medicine · doi:10.7326/m19-3888 · Cited by 57 · see citing works

Global neuropathologic severity of Alzheimer’s disease and locus coeruleus vulnerability influences plasma phosphorylated tau levels

Murray, M. E., Moloney, C. M., Kouri, N., Syrjanen, J. A., Matchett, B. J., Rothberg, D. M., Tranovich, J. F., Sirmans, T. N. H., Wiste, H. J., Boon, B. D. C., et al. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00578-0 · Cited by 58 · see citing works

The clinical feasibility of deep learning-based classification of amyloid PET images in visually equivocal cases

Son, H. J., Oh, J. S., Oh, M., Kim, S. J., Lee, J., Roh, J. H., & Kim, J. S. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04595-y · Cited by 54 · see citing works

Differential associations of APOE-ε2 and APOE-ε4 alleles with PET-measured amyloid-β and tau deposition in older individuals without dementia

Salvadó, G., Grothe, M. J., Groot, C., Moscoso, A., Schöll, M., Gispert, J. D., Ossenkoppele, R., & Initiative, A. D. N. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05192-8 · Cited by 54 · see citing works

Intrinsic connectivity of the human brain provides scaffold for tau aggregation in clinical variants of Alzheimer’s disease

Therriault, J., Pascoal, T. A., Savard, M., Mathotaarachchi, S. S., Benedet, A. L., Chamoun, M., Tissot, C., Lussier, F. Z., Rahmouni, N., Stevenson, J., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abc8693 · Cited by 54 · see citing works

Stress testing the Centiloid: Precision and variability of PET quantification of amyloid pathology

Shekari, M., García, D. V., Collij, L. E., Altomare, D., Heeman, F., Pemberton, H., Roé-Vellvé, N., Bullich, S., Buckley, C. J., Stephens, A. W., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13883 · Cited by 53 · see citing works

Harmonizing tau positron emission tomography in Alzheimer's disease: The CenTauR scale and the joint propagation model

Leuzy, A., Rakêt, L. L., Villemagne, V. L., Klein, G., Tonietto, M., Olafson, E., Baker, S. L., Saad, Z. S., Bullich, S., Lopresti, B. J., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13908 · Cited by 51 · see citing works

CSF biomarkers and plasma p‐tau181 as predictors of longitudinal tau accumulation: Implications for clinical trial design

Moscoso, A., Karikari, T. K., Grothe, M. J., Ashton, N. J., Lantero‐Rodriguez, J., Snellman, A., Zetterberg, H., Blennow, K., & Schöll, M. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12570 · Cited by 50 · see citing works

Baseline cognition is the best predictor of 4-year cognitive change in cognitively intact older adults

Schaeverbeke, J. M., Gabel, S., Meersmans, K., Luckett, E. S., Meyer, S. D., Adamczuk, K., Nelissen, N., Goovaerts, V., Radwan, A., Sunaert, S. G., et al. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00798-4 · Cited by 51 · see citing works

A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [18F]flutemetamol amyloid PET images

Bucci, M., Savitcheva, I., Farrar, G., Salvadó, G., Collij, L., Doré, V., Gispert, J. D., Gunn, R., Hanseeuw, B., Hansson, O., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05311-5 · Cited by 50 · see citing works

Increased Medial Temporal Tau Positron Emission Tomography Uptake in the Absence of Amyloid-β Positivity

Costoya‐Sánchez, A., Moscoso, A., Silva‐Rodríguez, J., Pontecorvo, M. J., Devous, M. D., Aguiar, P., Schöll, M., Grothe, M. J., Initiative, A. D. N., Weiner, M. W., et al. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2023.2560 · Cited by 48 · see citing works

Advances in Brain Amyloid Imaging

Krishnadas, N., Villemagne, V. L., Doré, V., & Rowe, C. C. (2021) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2020.12.005 · Cited by 48 · see citing works

Quantification Supports Amyloid PET Visual Assessment of Challenging Cases: Results from the AMYPAD Diagnostic and Patient Management Study

Collij, L. E., Bischof, G. N., Altomare, D., Bader, I., Battle, M. R., García, D. V., Alves, I. L., Wolz, R., Gismondi, R., Stephens, A. W., et al. (2024) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.268119 · Cited by 46 · see citing works

Plasma Aβ 42 /Aβ 40 is sensitive to early cerebral amyloid accumulation and predicts risk of cognitive decline across the Alzheimer's disease spectrum

Trelle, A. N., Young, C. B., Vossler, H. A., Benitez, J. A. R., Cody, K. A., Mendiola, J. H., Swarovski, M. S., Guen, Y. L., Feinstein, I., Butler, R. R., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14442 · Cited by 47 · see citing works

Quantitative Evaluation of 18F-Flutemetamol PET in Patients With Cognitive Impairment and Suspected Alzheimer's Disease: A Multicenter Study

Matsuda, H., Ito, K., Ishii, K., Shimosegawa, E., Okazawa, H., Mishina, M., Mizumura, S., Ishii, K., Okita, K., Shigemoto, Y., et al. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2020.578753 · Cited by 45 · see citing works

Validation of quantitative assessment of florbetaben PET scans as an adjunct to the visual assessment across 15 software methods

Jovalekic, A., Roé-Vellvé, N., Koglin, N., Lagos‐Quintana, M., Nelson, A. S., Diemling, M., Lilja, J., Gómez-González, J. P., Doré, V., Bourgeat, P., et al. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06279-0 · Cited by 45 · see citing works

Plasma P-tau181 and P-tau217 in Patients With Traumatic Encephalopathy Syndrome With and Without Evidence of Alzheimer Disease Pathology

Asken, B. M., Tanner, J. A., VandeVrede, L., Mantyh, W. G., Casaletto, K. B., Staffaroni, A. M., La Joie, R., Iaccarino, L., Soleimani-Meigooni, D., Rojas, J. C., et al. (2022) · Neurology · doi:10.1212/wnl.0000000000200678 · Cited by 40 · see citing works

Evaluation of Plasma Phosphorylated Tau217 for Differentiation Between Alzheimer Disease and Frontotemporal Lobar Degeneration Subtypes Among Patients With Corticobasal Syndrome

VandeVrede, L. A., Joie, R. L., Thijssen, E. H., Asken, B. M., Vento, S. A., Tsuei, T., Baker, S. L., Cobigo, Y., Fonseca, C. S., Heuer, H. W., et al. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2023.0488 · Cited by 44 · see citing works

Comparison of plasma biomarkers and amyloid PET for predicting memory decline in cognitively unimpaired individuals

Jack, C. R., Wiste, H. J., Algeciras‐Schimnich, A., Weigand, S. D., Figdore, D. J., Lowe, V. J., Vemuri, P., Graff‐Radford, J., Ramanan, V. K., Knopman, D. S., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13651 · Cited by 43 · see citing works

In vitro Characterization of the Regional Binding Distribution of Amyloid PET Tracer Florbetaben and the Glia Tracers Deprenyl and PK11195 in Autopsy Alzheimer’s Brain Tissue

Ni, R., Röjdner, J., Voytenko, L., Dyrks, T., Thiele, A., Marutle, A., & Nordberg, A. (2021) · Journal of Alzheimer's Disease · doi:10.3233/jad-201344 · Cited by 35 · see citing works

Longitudinal Phospho-tau217 Predicts Amyloid Positron Emission Tomography in Asymptomatic Alzheimer's Disease

Rissman, R. A., Donohue, M., Langford, O., Raman, R., Abdel‐Latif, S., Yaari, R., Holdridge, K. C., Sims, J. R., Molina‐Henry, D. P., Jimenez‐Maggiora, G. A., et al. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.134 · Cited by 43 · see citing works

Robustness of CSF Aβ42/40 and Aβ42/P‐tau181 measured using fully automated immunoassays to detect AD‐related outcomes

Leuzy, A., Mattsson, N., Cullen, N. C., Stomrud, E., Palmqvist, S., Joie, R. L., Iaccarino, L., Zetterberg, H., Rabinovici, G. D., Blennow, K., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.12897 · Cited by 43 · see citing works

Alzheimer's disease neuropathology and its estimation with fluid and imaging biomarkers

Thal, D. R., Poesen, K., Vandenberghe, R. R., & Meyer, S. D. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00819-y · Cited by 47 · see citing works

Concordance Between Amyloid-PET Quantification and Real-World Visual Reads

Zeltzer, E., Schonhaut, D. R., Mundada, N. S., Blazhenets, G., Mejía, J. A., Soleimani‐Meigooni, D. N., Cho, H., Ranasinghe, K. G., Windon, C., Yadollahikhales, G., et al. (2025) · JAMA Neurology · doi:10.1001/jamaneurol.2025.2218 · Cited by 42 · see citing works

Comparative pathological study of Carbon‐11 labeled Pittsburgh compound‐B PET Centiloid Scale and amyloid beta deposition in postmortem brains

Matsubara, T., Murayama, S., Ihara, R., Higashihara, M., Nishina, Y., Kanemaru, K., Iwata, A., Arai, T., Kameyama, M., Tokumaru, A. M., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.065244

Gene therapy PR001 increased GCase activity and improved neuronopathic Gaucher disease phenotypes in mouse models

Heckman, L. D., Sheehan, P., Fenn, T., Wong, L. C., Nelson, S., Garimalla, S., Haller, J. F., Daily, J., Politi, J., Dai, Y. D., et al. (2020) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2019.11.168 · Cited by 1 · see citing works

Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer’s disease

Amadoru, S., Doré, V., McLean, C. A., Hinton, F., Shepherd, C. E., Halliday, G. M., Leyton, C. E., Yates, P. A., Hodges, J. R., Masters, C. L., et al. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00587-5 · Cited by 181 · see citing works

Correspondence between in vivo 11C-PiB-PET amyloid imaging and postmortem, region-matched assessment of plaques

Driscoll, I., Troncoso, J. C., Rudow, G., Sojkova, J., Pletnikova, O., Zhou, Y., Kraut, M. A., Ferrucci, L., Mathis, C. A., Klunk, W. E., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1025-1 · Cited by 104 · see citing works

O2‐06‐05: CORRELATION OF AMYLOID PET EXPRESSED IN CENTILOID UNITS WITH NEUROPATHOLOGICAL FINDINGS IN ALZHEIMER'S DISEASE

Rowe, C. C., Amadoru, S., Doré, V., McLean, C., Hinton, F., Shepherd, C. E., Halliday, G. M., Leyton, C. E., Hodges, J. R., Masters, C. L., et al. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.06.2673 · Cited by 5 · see citing works